CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced that new investigational data on its marketed treatments for Fabry disease, Gaucher disease, MPS I and Pompe disease, along with data on its rare diseases pipeline, will be presented at the 12th annual WORLDSymposium. The symposium, which will be held in San Diego, CA, February 29 – March 4, is focused on scientific research and clinical trials for lysosomal storage disorders. Sanofi Genzyme will sponsor 19 presentations including six platform presentations from across its lysosomal storage disorder (LSD) portfolio and rare disease pipeline.
